These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29286471)

  • 1. In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease.
    Lukas J; Knospe AM; Seemann S; Citro V; Cubellis MV; Rolfs A
    J Vis Exp; 2017 Dec; (130):. PubMed ID: 29286471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T).
    Ebrahim HY; Baker RJ; Mehta AB; Hughes DA
    J Inherit Metab Dis; 2012 Mar; 35(2):325-34. PubMed ID: 21972175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysosomal storage disorders: Novel and frequent pathogenic variants in a large cohort of Indian patients of Pompe, Fabry, Gaucher and Hurler disease.
    Thomas DC; Sharma S; Puri RD; Verma IC; Verma J
    Clin Biochem; 2021 Mar; 89():14-37. PubMed ID: 33301762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein structural features predict responsiveness to pharmacological chaperone treatment for three lysosomal storage disorders.
    Woodard J; Zheng W; Zhang Y
    PLoS Comput Biol; 2021 Sep; 17(9):e1009370. PubMed ID: 34529671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease.
    Lukas J; Cimmaruta C; Liguori L; Pantoom S; Iwanov K; Petters J; Hund C; Bunschkowski M; Hermann A; Cubellis MV; Rolfs A
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme enhancers for the treatment of Fabry and Pompe disease.
    Lukas J; Pockrandt AM; Seemann S; Sharif M; Runge F; Pohlers S; Zheng C; Gläser A; Beller M; Rolfs A; Giese AK
    Mol Ther; 2015 Mar; 23(3):456-64. PubMed ID: 25409744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests.
    Andreotti G; Citro V; De Crescenzo A; Orlando P; Cammisa M; Correra A; Cubellis MV
    Orphanet J Rare Dis; 2011 Oct; 6():66. PubMed ID: 22004918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Looking for protein stabilizing drugs with thermal shift assay.
    Andreotti G; Monticelli M; Cubellis MV
    Drug Test Anal; 2015 Sep; 7(9):831-4. PubMed ID: 25845367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification.
    Keyzor I; Shohet S; Castelli J; Sitaraman S; Veleva-Rotse B; Weimer JM; Fox B; Willer T; Tuske S; Crathorne L; Belzar KJ
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of oral and craniofacial findings in patients with Fabry disease or Pompe disease.
    Benz K; Hahn P; Hanisch M; Lücke K; Lücke T; Jackowski J
    Br J Oral Maxillofac Surg; 2019 Nov; 57(9):831-838. PubMed ID: 31405600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations.
    Citro V; Cammisa M; Liguori L; Cimmaruta C; Lukas J; Cubellis MV; Andreotti G
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations.
    Liguori L; Monticelli M; Allocca M; Hay Mele B; Lukas J; Cubellis MV; Andreotti G
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-based screening of active-site specific chaperone for the treatment of Fabry disease.
    Fan JQ; Ishii S
    Methods Enzymol; 2003; 363():412-20. PubMed ID: 14579593
    [No Abstract]   [Full Text] [Related]  

  • 14. A thermodynamic assay to test pharmacological chaperones for Fabry disease.
    Andreotti G; Citro V; Correra A; Cubellis MV
    Biochim Biophys Acta; 2014 Mar; 1840(3):1214-24. PubMed ID: 24361605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
    Sánchez-Fernández EM; García Fernández JM; Mellet CO
    Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological Chaperone Therapy for Fabry Disease].
    Kobayashi M
    Brain Nerve; 2024 Oct; 76(10):1137-1143. PubMed ID: 39370838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.
    Parenti G
    EMBO Mol Med; 2009 Aug; 1(5):268-79. PubMed ID: 20049730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment.
    Haneef SA; Doss CG
    Adv Protein Chem Struct Biol; 2016; 102():225-65. PubMed ID: 26827607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inter-assay variability influences migalastat amenability assessments among Fabry disease variants.
    Oommen S; Zhou Y; Meiyappan M; Gurevich A; Qiu Y
    Mol Genet Metab; 2019 May; 127(1):74-85. PubMed ID: 31036492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.